Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab

Ophthalmologica

Volumn 223, Issue 4, 2009, Pages 279-282

  Karagiannis, Dimitrios A ^a   Mitropoulos, Panagiotis ^a   Ladas, Ioannis D ^b  

^a Eye Hospital of Athens   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Age related macular degeneration; Bevacizumab; Ranibizumab; Subretinal haemorrhage

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; BIOMICROSCOPY; CASE REPORT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; SLIT LAMP; SYSTEMIC DISEASE; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; RETINAL HEMORRHAGE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 65449152660     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000213644     Document Type: Article

References (14)

1. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP: Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-293.
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
3. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
4. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzales S, Feuer WJ, Lin GA, Laiwani GA, Nguyen JK, Kumar G: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
5. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN: Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008; 145:249-256.
6. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
7. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N, PIER Study Group: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145:239-248.
8. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, MARINA Study Group: Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007;125:1460-1469.
9. Bhatnagar P, Spaide RF, Takahashi BS, Peragallo JH, Freund KB, Klancnik JM, Cooney MJ, Slakter JS, Sorenson JA, Yannuzzi LA: Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2007;27:846-850.
10. Bakri SJ, Kitzmann AS: Retinal epithelial tear after intravitreal ranibizumab. Am J Ophtha lmol 2007;143:505-507.
11. Scupola A, Coscas G, Soubrane G, Bale-strazzi E: Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 1999;213:97-102.
12. Stifter E, Michels S, Prager F, Georgopoulos M, Polak K, Hirn C, Schmidt-Erfurth U: Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007;144:886-892.
13. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-2182.
14. Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA: Pharmakokinetics and retinal distribution of ranibizum-ab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27:1260-1266.